Bristol-Myers Squibb/ImaRx Pharmaceutical
This article was originally published in The Gray Sheet
Executive SummaryFirms enter into licensing agreement whereby Bristol-Myers acquires manufacturing and marketing rights to SonoRx, an orally administered ultrasound contrast agent developed by ImaRx. According to Bristol-Myers, "SonoRx may allow physicians to see . . . internal organs more easily by eliminating the gas artifacts that can prevent clear delineation of structures" during abdominal ultrasound procedures. The firm says it intends to submit an investigational new drug application for SonoRx in 1993 and complete clinical trials during 1994. It adds that its subsidiary Westwood Squibb of Buffalo, New York will manufacture the agent.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.